Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q3 2019 · 10-Q
Revenue$92.06M$92.06M+42.2% vs Q3 2018 Net Income$1.93M$1.93MN/M vs Q3 2018 EPS Diluted$0.02$0.02N/M vs Q3 2018 Gross Profit$69,162,000+51.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow$14,907,000+164.4% Free Cash Flowderived$12,199,000+184.7% Margins · derivedGross margin75.1%+4.4 pt vs Q3 2018
Operating margin4.2%+12.3 pt vs Q3 2018
Net margin2.1%+20.2 pt vs Q3 2018
ended Sep 30, 2019 · filed Oct 31, 2019 · 31 d after period end